DiaMedica Therapeutics Inc
DMAC8.230USD
-0.240-2.83%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
354.49MMarket Cap
LossP/E TTM
More Details of DiaMedica Therapeutics Inc Company
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
DiaMedica Therapeutics Inc Info
Ticker SymbolDMAC
Company nameDiaMedica Therapeutics Inc
IPO dateJan 04, 2008
CEOPauls (Rick)
Number of employees27
Security typeOrdinary Share
Fiscal year-endJan 04
Address301 Carlson Parkway
CityMINNEAPOLIS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code55305
Phone17634965454
Websitehttps://www.diamedica.com/
Ticker SymbolDMAC
IPO dateJan 04, 2008
CEOPauls (Rick)
Company Executives of DiaMedica Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Scott Kellen
Mr. Scott Kellen
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
32.29K
--
Mr. David J. (Dave) Wambeke
Mr. David J. (Dave) Wambeke
Chief Business Officer
Chief Business Officer
--
--
Mr. Daniel J. (Dan) O'Connor, J.D.
Mr. Daniel J. (Dan) O'Connor, J.D.
Independent Director
Independent Director
--
--
Ms. Tanya N. Lewis
Ms. Tanya N. Lewis
Independent Director
Independent Director
--
--
Mr. James T. (Jim) Parsons, CPA
Mr. James T. (Jim) Parsons, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Rick Pauls
Mr. Rick Pauls
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Charles P. Semba, M.D.
Dr. Charles P. Semba, M.D.
Independent Director
Independent Director
--
--
Dr. Richard E. Kuntz, M.D.
Dr. Richard E. Kuntz, M.D.
Independent Director
Independent Director
--
--
Dr. Michael Giuffre, M.D.
Dr. Michael Giuffre, M.D.
Independent Director
Independent Director
--
--
Dr. Julie Krop, M.D.
Dr. Julie Krop, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Scott Kellen
Mr. Scott Kellen
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
32.29K
--
Mr. David J. (Dave) Wambeke
Mr. David J. (Dave) Wambeke
Chief Business Officer
Chief Business Officer
--
--
Mr. Daniel J. (Dan) O'Connor, J.D.
Mr. Daniel J. (Dan) O'Connor, J.D.
Independent Director
Independent Director
--
--
Ms. Tanya N. Lewis
Ms. Tanya N. Lewis
Independent Director
Independent Director
--
--
Mr. James T. (Jim) Parsons, CPA
Mr. James T. (Jim) Parsons, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Rick Pauls
Mr. Rick Pauls
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
EQT Partners AB
16.10%
Trill AB,LLC.
14.91%
Jacinto (Richard II)
9.52%
Omega Advisors, Inc.
6.28%
B. Riley Asset Management, LLC
4.24%
Other
48.96%
Shareholders
Shareholders
Proportion
EQT Partners AB
16.10%
Trill AB,LLC.
14.91%
Jacinto (Richard II)
9.52%
Omega Advisors, Inc.
6.28%
B. Riley Asset Management, LLC
4.24%
Other
48.96%
Shareholder Types
Shareholders
Proportion
Private Equity
16.10%
Corporation
14.91%
Individual Investor
11.39%
Investment Advisor
9.26%
Investment Advisor/Hedge Fund
8.17%
Family Office
6.28%
Hedge Fund
4.17%
Research Firm
1.06%
Bank and Trust
0.06%
Other
28.60%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
139
20.19M
25.98%
-122.00
2025Q3
140
20.19M
26.39%
+5.22M
2025Q2
121
14.97M
28.56%
+1.16M
2025Q1
92
13.81M
27.02%
+2.23M
2024Q4
83
13.03M
21.87%
+1.04M
2024Q3
72
11.99M
20.72%
+405.53K
2024Q2
67
11.58M
23.71%
+3.35M
2024Q1
70
8.23M
20.59%
+410.81K
2023Q4
74
7.47M
21.43%
-247.59K
2023Q3
74
7.72M
19.42%
+763.37K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
EQT Partners AB
8.38M
16.22%
+2.86M
+51.70%
Jul 23, 2025
Trill AB,LLC.
7.76M
15.02%
+1.00M
+14.78%
Aug 14, 2025
Jacinto (Richard II)
4.96M
9.59%
+400.00K
+8.77%
Jul 23, 2025
Omega Advisors, Inc.
1.65M
3.19%
+25.00K
+1.54%
Jun 30, 2025
B. Riley Asset Management, LLC
2.21M
4.27%
+2.21M
--
Jun 28, 2024
BlackRock Institutional Trust Company, N.A.
1.06M
2.05%
+959.98K
+941.19%
Jun 30, 2025
Paragon JV Partners, LLC
650.00K
1.26%
+50.00K
+8.33%
Jun 30, 2025
Geode Capital Management, L.L.C.
630.15K
1.22%
+314.41K
+99.58%
Jun 30, 2025
The Vanguard Group, Inc.
1.54M
2.97%
+183.59K
+13.58%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.04%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proportion0.04%
ProShares UltraPro Russell2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of DiaMedica Therapeutics Inc?
The top five shareholders of DiaMedica Therapeutics Inc are:
EQT Partners AB holds 8.38M shares, accounting for 16.22% of the total shares.
Trill AB,LLC. holds 7.76M shares, accounting for 15.02% of the total shares.
Jacinto (Richard II) holds 4.96M shares, accounting for 9.59% of the total shares.
Omega Advisors, Inc. holds 1.65M shares, accounting for 3.19% of the total shares.
B. Riley Asset Management, LLC holds 2.21M shares, accounting for 4.27% of the total shares.
EQT Partners AB holds 8.38M shares, accounting for 16.22% of the total shares.
Trill AB,LLC. holds 7.76M shares, accounting for 15.02% of the total shares.
Jacinto (Richard II) holds 4.96M shares, accounting for 9.59% of the total shares.
Omega Advisors, Inc. holds 1.65M shares, accounting for 3.19% of the total shares.
B. Riley Asset Management, LLC holds 2.21M shares, accounting for 4.27% of the total shares.
What are the top three shareholder types of DiaMedica Therapeutics Inc?
The top three shareholder types of DiaMedica Therapeutics Inc are:
EQT Partners AB
Trill AB,LLC.
Jacinto (Richard II)
EQT Partners AB
Trill AB,LLC.
Jacinto (Richard II)
How many institutions hold shares of DiaMedica Therapeutics Inc (DMAC)?
As of 2025Q4, 139 institutions hold shares of DiaMedica Therapeutics Inc, with a combined market value of approximately 20.19M, accounting for 25.98% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.41%.
What is the biggest source of revenue for DiaMedica Therapeutics Inc?
In --, the -- business generated the highest revenue for DiaMedica Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
